1 års afkast (CAGR)
3.76%
Bavarian Nordic Exchange (CO, DKK)
BAVA.CO
251.20
+3.80 (+1.54%)
HealthcareBiotechnology
Loading...
3 års afkast (CAGR)
23.09%
5 års afkast (CAGR)
-4.97%
10 års afkast (CAGR)
4.56%
Adobe 2026 Q3 – Er det stemningen, der driver prisen?
Læs mereMarkedsværdi
18.90B
Pris/omsætning
3.00
Ent værdi
19.63B
Pris/bog
1.43
Udbytte afkast
0.00%
Vekst år
-
Udbyttevækst
-
FCF-udbetaling
0.00%
Efterfølgende P/E
12.25
PEG
-
Fremtidig P/E
23.88
EPS-vekst
27.98%
Oplysninger om aktier
Hvad er en børs? Drift, aktører, eksempler
Læs mereAktiediagram
Loading...
Aktiekurs-data
| Åbning | 247.40 |
| Daglig høj | 251.40 |
| Daglig lav | 246.40 |
| Daglig volumen | 249K |
| Højeste gennem alle tider | 401.70 |
| 1 års analytiker estimat | 276.25 |
| Beta | 0.97 |
| EPS (TTM) | 20.31 |
| Udbytte pr. aktie | 0.00 |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 12 Mar 2026 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| BAVA.CO | S&P500 | |
| Nuværende prisfald fra top notering | -37.47% | -1.76% |
| Højeste prisfald | -91.83% | -56.47% |
| Højeste efterår dato | 30 Sep 2002 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -48.25% | -10.65% |
| Gennemsnitlig tid til nyt højdepunkt | 101 days | 12 days |
| Maks. tid til nyt højdepunkt | 1935 days | 1805 days |
Nyheder
COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on September 1, 2026, has now been completed, reach...
2. november 2026
COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has been awarded a new multi-year contract by the UK Government through the UK Health Security Agency (U...
2. november 2026
Bavarian Nordic donates 75,000 doses of MVA-BN® and will also supply 150,000 doses to new global mpox vaccine emergency stockpile.Building emergency reserves is an important milestone in global mpox p...
27. oktober 2026
COPENHAGEN, Denmark, October 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase s...
26. oktober 2026
Bavarian Nordic has put in a strong three year share price run, while fresh optimism around its vaccines business has sharpened the focus on what the current valuation implies about the cash the compa...
9. oktober 2026
Bavarian Nordic (CPSE:BAVA) raised its full-year 2026 guidance following stronger Travel Health activity, with increased rabies vaccine demand in the US supporting both a higher revenue outlook and a ...
9. oktober 2026
Investing.com -- Bavarian Nordic shares rose around 4% Thursday after the company raised its full-year 2026 guidance again, lifting its revenue and profitability outlook on stronger-than-expected sale...
8. oktober 2026
Revenue and EBITDA margin expectations increased, driven by stronger-than-expected Travel Health sales COPENHAGEN, Denmark, October 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade...
8. oktober 2026
The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.
28. september 2026
COPENHAGEN, Denmark, September 22, 2026 - Pursuant to Section 31 of the Danish Capital Markets Act, it is hereby announced that as of September 21, 2026, Bavarian Nordic’s holding of treasury shares a...
22. september 2026